sj-pdf-5-tar-10.1177_17534666211009398 – Supplemental material for Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study

MLA

Detoraki, Aikaterini, et al. Sj-Pdf-5-Tar-10.1177_17534666211009398 – Supplemental Material for Mepolizumab Improves Sino-Nasal Symptoms and Asthma Control in Severe Eosinophilic Asthma Patients with Chronic Rhinosinusitis and Nasal Polyps: A 12-Month Real-Life Study. Jan. 2021. EBSCOhost, https://doi.org/10.25384/sage.14560945.v1.

APA

Detoraki, A., Tremante, E., D, A. M., Calabrese, C., Casella, C., Maniscalco, M., Poto, R., Brancaccio, R., Boccia, M., Martino, M., Imperatore, C., & Spadaro, G. (2021). sj-pdf-5-tar-10.1177_17534666211009398 – Supplemental material for Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. https://doi.org/10.25384/sage.14560945.v1

Chicago

Detoraki, Aikaterini, Eugenio Tremante, Amato, Maria D, Cecilia Calabrese, Claudia Casella, Mauro Maniscalco, Remo Poto, et al. 2021. “Sj-Pdf-5-Tar-10.1177_17534666211009398 – Supplemental Material for Mepolizumab Improves Sino-Nasal Symptoms and Asthma Control in Severe Eosinophilic Asthma Patients with Chronic Rhinosinusitis and Nasal Polyps: A 12-Month Real-Life Study,” January. doi:10.25384/sage.14560945.v1.